open access

Vol 77, No 2 (2009)
EDUCATION
Published online: 2009-03-16
Submitted: 2013-02-22
Get Citation

End stage chronic obstructive pulmonary disease

Nicolino Ambrosino, Marco Gherardi, Nicoletta Carpenè
Pneumonol Alergol Pol 2009;77(2):173-179.

open access

Vol 77, No 2 (2009)
EDUCATION
Published online: 2009-03-16
Submitted: 2013-02-22

Abstract

Many patients with chronic obstructive pulmonary disease (COPD) die each year as those with lung cancer but current guidelines make few recommendations on the care for the most severe patients i.e. those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III and IV with chronic respiratory failure.
Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD. Although non invasive positive pressure ventilation (NPPV) may have an adjunctive role in the management of chronic respiratory insufficiency there is little evidence for its use in the routine management of stable hypercapnic COPD patients. At difference, several prospective, randomised, controlled studies, systematic reviews and meta-analyses show good level of evidence for clinical efficacy of NPPV in the treatment of acute on chronic respiratory failure due to acute exacerbations of COPD. NPPV is also alternative to invasive ventilation for symptom relief in end stage COPD.
Surgical interventions for end stage COPD like bullectomy, different modalities of lung volume reduction surgery and lung transplantation are likely to be of value to only a small percentage of patients. Nevertheless, there are specific indications, which, when added to pulmonary rehabilitation will further advance exercise capacity and quality of life. As in other chronic diseases when severity of disease increases along the natural history, therapy aimed to prolong life becomes less and less important in comparison to palliative therapy aimed to relieve symptoms. The most effective treatments for dyspnoea are bronchodilators, although also opiates may improve dyspnoea. Supplemental oxygen reduce exertional breathlessness and improve exercise tolerance in hypoxaemic COPD patients. There are difficulties in treating with antidepressant the frail and elderly COPD patients.
Good clinical care can prevent or alleviate suffering by assessing symptoms and providing psychological and social support to the patients and their families.

Abstract

Many patients with chronic obstructive pulmonary disease (COPD) die each year as those with lung cancer but current guidelines make few recommendations on the care for the most severe patients i.e. those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III and IV with chronic respiratory failure.
Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD. Although non invasive positive pressure ventilation (NPPV) may have an adjunctive role in the management of chronic respiratory insufficiency there is little evidence for its use in the routine management of stable hypercapnic COPD patients. At difference, several prospective, randomised, controlled studies, systematic reviews and meta-analyses show good level of evidence for clinical efficacy of NPPV in the treatment of acute on chronic respiratory failure due to acute exacerbations of COPD. NPPV is also alternative to invasive ventilation for symptom relief in end stage COPD.
Surgical interventions for end stage COPD like bullectomy, different modalities of lung volume reduction surgery and lung transplantation are likely to be of value to only a small percentage of patients. Nevertheless, there are specific indications, which, when added to pulmonary rehabilitation will further advance exercise capacity and quality of life. As in other chronic diseases when severity of disease increases along the natural history, therapy aimed to prolong life becomes less and less important in comparison to palliative therapy aimed to relieve symptoms. The most effective treatments for dyspnoea are bronchodilators, although also opiates may improve dyspnoea. Supplemental oxygen reduce exertional breathlessness and improve exercise tolerance in hypoxaemic COPD patients. There are difficulties in treating with antidepressant the frail and elderly COPD patients.
Good clinical care can prevent or alleviate suffering by assessing symptoms and providing psychological and social support to the patients and their families.
Get Citation
About this article
Title

End stage chronic obstructive pulmonary disease

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 2 (2009)

Pages

173-179

Published online

2009-03-16

Bibliographic record

Pneumonol Alergol Pol 2009;77(2):173-179.

Authors

Nicolino Ambrosino
Marco Gherardi
Nicoletta Carpenè

References (74)
  1. Global initiative for chronic obstructive lung disease. Workshop report, global strategy for diagnosis, management, and prevention of COPD. Update Sept 2005. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute. www.goldcopd.com. (2005).
  2. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6): 932–946.
  3. Zielinski J, Bednarek M, Górecka D, et al. Increasing COPD awareness. Eur Respir J. 2006; 27(4): 833–852.
  4. Connors AF, et al. Jr, Dawson N.V., Thomas C. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.
  5. Vitacca M, Bianchi L, Barbano L, et al. Effects of acute on chronic respiratory failure on hypercapnia and 3-month survival. Chest. 2005; 128(3): 1209–1215.
  6. Groenewegen KH, Schols AM, Wouters EFM. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124(2): 459–467.
  7. Rivera-Fernández R, Navarrete-Navarro P, Fernández-Mondejar E, et al. Project for the Epidemiological Analysis of Critical Care Patients (PAEEC) Group. Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit Care Med. 2006; 34(9): 2317–2324.
  8. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31(1): 204–212.
  9. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61(1): 23–28.
  10. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32(4): 962–969.
  11. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178(12): 1211–1218.
  12. Restrick LJ, Paul EA, Braid GM, et al. Assessment and follow up of patients prescribed long term oxygen treatment. Thorax. 1993; 48(7): 708–713.
  13. Schols A, Wouters E. Nutrition and metabolic therapy. In: Donner CF, Ambrosino N, Goldstein RS. ed. Pulmonary Rehabilitation. . Hodder Arnold, London 2005: 229–235.
  14. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1791–1797.
  15. Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J. 2008; 31(3): 667–677.
  16. Ambrosino N, Bruletti G, Scala V, et al. Cognitive and perceived health status in patients recovering from an acute exacerbation of COPD. A controlled study. Intensive Care Med. 2002; 28: 170–177.
  17. Albert P, Calverley PMA. Drugs (including oxygen) in severe COPD. Eur Respir J. 2008; 31(5): 1114–1124.
  18. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300(20): 2407–2416.
  19. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005; 60(12): 992–997.
  20. Sin DD, Man SF, Marciniuk DD, et al. ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 177(11): 1207–1214.
  21. Calverley PMA, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8): 775–789.
  22. Cano NJM, Pichard C, Roth H, et al. Clinical Research Group of the Société Francophone de Nutrition Entérale et Parentérale. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest. 2004; 126(2): 540–546.
  23. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300(12): 1439–1450.
  24. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543–1554.
  25. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008; 178(7): 695–700.
  26. Mitrouska I, Tzanakis N, Siafakas NM. Oxygen therapy in chronic obstructive pulmonary disease. Management of Chronic Obstructive Pulmonary Disease. 2006: 302–312.
  27. Petty TL, O'Donohue WJ. Further recommendations for prescribing, reimbursement, technology development, and research in long-term oxygen therapy. Summary of the Fourth Oxygen Consensus Conference, Washington, D.C., October 15-16, 1993. Am J Respir Crit Care Med. 1994; 150(3): 875–877.
  28. Nonoyama ML, Brooks D, Lacasse Y, et al. Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(2): CD005372.
  29. Nonoyama ML, Brooks D, Guyatt GH, et al. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med. 2007; 176(4): 343–349.
  30. Hanania NA, Ambrosino N, Calverley P, et al. Treatments for COPD. Respir Med. 2005; 99 Suppl B: S28–S40.
  31. Muir JF, Cuvelier A, Tenang B. European task force on mechanical ventilation COPD. Long-term home nasal intermittent positive pressure ventilation (NIPPV) plus oxygen therapy (LTOT) versus LTOT alone in severe hypercapnic COPD. Preliminary results of a European multicentre trial. Am. J. Respir. Crit. Care Med. 1997; 155: A408.
  32. Clini E, Sturani C, Rossi A, et al. Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002; 20(3): 529–538.
  33. Windisch W. Quality of life in home mechanical ventilation study group. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J. 2008; 32(5): 1328–1336.
  34. Kolodziej MA, Jensen L, Rowe B, et al. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J. 2007; 30(2): 293–306.
  35. Barnes PJ, Burney PGJ, Silverman EK, et al. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007; 29(6): 1224–1238.
  36. Garcia-Aymerich J, Monsó E, Marrades RM, et al. EFRAM Investigators. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med. 2001; 164(6): 1002–1007.
  37. Esteban A, Ferguson ND, Meade MO, et al. VENTILA Group. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008; 177(2): 170–177.
  38. Ambrosino N, Vagheggini G. Noninvasive positive pressure ventilation in the acute care setting: where are we? Eur Respir J. 2008; 31(4): 874–886.
  39. Sinuff T, Cook DJ, Keenan SP, et al. Noninvasive ventilation for acute respiratory failure near the end of life. Crit Care Med. 2008; 36(3): 789–794.
  40. Nava S, Sturani C, Hartl S, et al. European Respiratory Society Task Force on Ethics and decision-making in end stage lung disease. End-of-life decision-making in respiratory intermediate care units: a European survey. Eur Respir J. 2007; 30(1): 156–164.
  41. Curtis JR, Cook DJ, Sinuff T, et al. Society of Critical Care Medicine Palliative Noninvasive Positive VentilationTask Force. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy. Crit Care Med. 2007; 35(3): 932–939.
  42. Ambrosino N, Casaburi R, Ford G, et al. Developing concepts in the pulmonary rehabilitation of COPD. Respir Med. 2008; 102 Suppl 1: S17–S26.
  43. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine. 2006; 173(12): 1390–1413.
  44. Carone M, Patessio A, Ambrosino N, et al. Efficacy of pulmonary rehabilitation in chronic respiratory failure (CRF) due to chronic obstructive pulmonary disease (COPD): The Maugeri Study. Respir Med. 2007; 101(12): 2447–2453.
  45. Clini E, Ambrosino N. Early physiotherapy in the respiratory intensive care unit. Respir Med. 2005; 99(9): 1096–1104.
  46. Porta R, Vitacca M, Gilè LS, et al. Supported arm training in patients recently weaned from mechanical ventilation. Chest. 2005; 128(4): 2511–2520.
  47. Gosselink R, Bott J, Johnson M, et al. Physiotherapy for adult patients with critical illness: recommendations of the European Respiratory Society and European Society of Intensive Care Medicine Task Force on Physiotherapy for Critically Ill Patients. Intensive Care Med. 2008; 34(7): 1188–1199.
  48. Ambrosino N, Palmiero G, Strambi SK. New approaches in pulmonary rehabilitation. Clin Chest Med. 2007; 28(3): 629–638.
  49. Lederer DJ, Arcasoy SM. Update in surgical therapy for chronic obstructive pulmonary disease. Clin Chest Med. 2007; 28(3): 639–653.
  50. Fishman A, Fessler H, Martinez F, et al. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345(15): 1075–1083.
  51. Fishman A, Martinez F, Naunheim K, et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003; 348(21): 2059–2073.
  52. Criner GJ, Scharf SM, Falk JA, et al. National Emphysema Treatment Trial Research Group. Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med. 2007; 176(3): 253–260.
  53. Washko GR, Fan VS, Ramsey SD, et al. National Emphysema Treatment Trial Research Group. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 177(2): 164–169.
  54. Ingenito EP, Tsai LW. Evolving endoscopic approaches for treatment of emphysema. Semin Thorac Cardiovasc Surg. 2007; 19(2): 181–189.
  55. Reilly J, Washko G, Pinto-Plata V, et al. Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest. 2007; 131(4): 1108–1113.
  56. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant. 2007; 26(8): 782–795.
  57. Corris PA, Christie JD. Update in transplantation 2007. Am J Respir Crit Care Med. 2008; 177(10): 1062–1067.
  58. Ambrosino N, Bruschi C, Callegari G, et al. Time course of exercise capacity, skeletal and respiratory muscle performance after heart-lung transplantation. Eur Respir J. 1996; 9(7): 1508–1514.
  59. Gay S, Martinez F. Pulmonary rehabilitation and transplantation. Pulmonary Rehabilitation. 2013: 304–311.
  60. ISHLT Transplant Registry Quarterly Reports. http://www.ishlt.org/registries/quarterlyDataReport.asp (16.12.2008).
  61. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008; 32(3): 796–803.
  62. Ambrosino N, Simonds A. The clinical management in extremely severe COPD. Respir Med. 2007; 101(8): 1613–1624.
  63. Luce J, Luce J. Management of Dyspnea in Patients With Far-Advanced Lung Disease. JAMA. 2001; 285(10): 1331–1337.
  64. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999; 159(1): 321–340.
  65. Wilcock A, Walton A, Manderson C, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax. 2008; 63(10): 872–875.
  66. Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax. 2008; 63(7): 606–613.
  67. Palange P, Crimi E, Pellegrino R, et al. Supplemental oxygen and heliox: 'new' tools for exercise training in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2005; 11(2): 145–148.
  68. Laude EA, Duffy NC, Baveystock C, et al. The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med. 2006; 173(8): 865–870.
  69. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008; 178(9): 913–920.
  70. Paz-Díaz H, Montes de Oca M, López JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007; 86(1): 30–36.
  71. Qaseem A, Snow V, Shekelle P, et al. Evidence-Based Interventions to Improve the Palliative Care of Pain, Dyspnea, and Depression at the End of Life: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine. 2008; 148(2): 141–146.
  72. Truog RD, Campbell ML, Curtis JR, et al. American Academy of Critical Care Medicine. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American College [corrected] of Critical Care Medicine. Crit Care Med. 2008; 36(3): 953–963.
  73. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med. 2008; 148(2): 147–159.
  74. Clini EM, Ambrosino N. Nonpharmacological treatment and relief of symptoms in COPD. Eur Respir J. 2008; 32(1): 218–228.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl